Coronavirus, WHO: 'No benefit from Remdesivir'

"The interim results of the Solidarity Therapeutics Trial, coordinated by WHO, indicate that remdesivir, hydroxychloroquine, lopinavir / ritonavir combination, and interferon-based regimens appear to have little or no effect on 28-day mortality or course Covid-19 hospital among hospitalized patients ".

The World Health Organization writes it in a statement, according to which remdesivir, one of the two drugs approved in Europe against the coronavirus that has recently been used also to treat US President Donald Trump, is also 'rejected'.

The study was conducted in 405 hospitals in 30 countries involving 11,266 adults, of whom 2750 received remdesivir, while 4088 received placebo. "The trial - reads the statement - investigated the effects of these treatments on overall mortality, on the initiation of intubation and on the length of hospitalization. Other uses of therapies, for example on the treatment of patients in communities or for prevention, they will be examined in different trials ". The remdesivir was approved by the EMA last June, mainly on the basis of a study conducted by the US Nih according to which the average hospitalization was reduced from 15 to 11 days in severe patients. It is the only drug approved by the authority to date along with dexamethasone.